Drugs / Lycopene
Lycopene
also known as
(all-e)-lycopene · (all-trans)-lycopene · Aec lycopene · Ateronon · Blakeslea trispora · Ci 75125 · E-160D(III) · E160d · +12 more
Other / unclassified targets PCNA via inhibition
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01949519 | Nov 2013 → Jun 2015 | prostate adenocarcinoma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT00178113 | Jul 2003 → Jul 2004 | prostate intraepithelial neoplasia | University of Pittsburgh | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03203746 | Sep 2015 → Nov 2016 | chronic periodontitis | Maie Sami tawfik | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT03964935 | Dec 2018 → Aug 2019 | periodontal disorder | University of Baghdad | Unknown | No outcome recorded |
| Phase 2 | NCT03167268 | Aug 2016 → Jan 2020 | colorectal cancer, toxic dermatosis | Ospedale San Carlo Borromeo | Unknown | No outcome recorded |
| Phase 2 | NCT02421887 | Dec 2015 → Jun 2018 | male infertility | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT01882985 | Dec 2010 → Oct 2016 | prostate adenocarcinoma | University of California, Irvine | Completed | No outcome recorded |
| Phase 2 | NCT00905931 | Sep 2010 → Jun 2012 | brain aneurysm, subarachnoid hemorrhage | University of Cambridge | Unknown | No outcome recorded |
| Phase 2 | NCT00844792 | Oct 2008 → Dec 2013 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT00744549 | May 2008 → Dec 2013 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT00450749 | Feb 2008 → May 2010 | prostate adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01443026 | Feb 2006 → Apr 2009 | prostate intraepithelial neoplasia | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 2 | NCT00172367 | Jan 2006 → ? | transitional cell carcinoma | National Taiwan University Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00154843 | Mar 2004 → Jun 2005 | benign prostatic hyperplasia | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04652739 | Oct 2018 → Mar 2019 | oral erosive lichen | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05614349 | Jan 2023 → Apr 2025 overdue | COVID-19 | Unity Health Toronto | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00939237 | Jul 2009 → May 2011 | coronary artery disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02587117 | Feb 2013 → Jan 2014 | lichen planus, oral | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02263352 | Jan → Mar 2013 | — | Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01102504 | Aug 2015 → Dec 2017 | carotid artery disorder | Cambridge University Hospitals NHS Foundation Trust | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00656214 Comparator | Dec 2004 → May 2006 | lichen planus, oral | College of Dental Sciences, India | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02714543 Comparator | Nov 2013 → Aug 2015 | oral submucous fibrosis | The Oxford Dental College, Hospital and Research Center, Bangalore, India | Completed | No outcome recorded |
| Phase 3 | NCT01287182 Comparator | May → Dec 2011 | atherosclerosis | Omicron Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01377961 Comparator | Sep 2010 → Aug 2015 | metabolic syndrome X, type 2 diabetes mellitus | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lycopene | “SM Fibro (Alpha lipoic acid 50mg, Beta-carotene 10mg, Elemental copper 1mg, Elemental selenium 75mcg, Lycopene 5mg, Vitamin E 10 IU, Zinc sulphate 27.45mg in form of the...” NCT02714543 ↗22“Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU,...” NCT02421887 ↗ “The second therapeutic arm investigates a combination antioxidant therapy (selenium 300 µg, zinc 40 mg, lycopene 45 mg and vitamin C 1.5 g), administered for 10 days.” PMID 40754325 ↗ Aug 2025 “Ateronon is a lycopene supplement developed with the understanding that the potential clinical effectiveness of lycopene is impacted by its bioavailability.” NCT00939237 ↗ “Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU” NCT00844792 ↗ “The study will use the properties of a tomato extract containing lycopene.” NCT01102504 ↗ “Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E” NCT00744549 ↗ “lycopene 30 mg capsules orally (PO) once daily on days 1-21” NCT01882985 ↗ “Lycopene 8mgms taken orally ,one per day for two months.” NCT02263352 ↗ |
| Known as | (all-e)-lycopene | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | (all-trans)-lycopene | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Aec lycopene | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Ateronon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01287182 ↗ |
| Known as | Blakeslea trispora | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Ci 75125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | E-160D(III) | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | E160d | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | FEMA NO. 4110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | INS NO.160D(III) | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | INS-160D(III) | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Lycopene from blakeslea trispora | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Lycopene preparation | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Lycored | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Mexoryl saq | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | NSC-407322 | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Redivivo | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Solanorubin | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Tomat-o-red | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Known as | Tomato lycopene | ChEMBL registry synonym — accepted as the source's own label CHEMBL501174 ↗ |
| Action | Inhibit | “down-regulating 5-alpha-reductase activity” NCT00450749 ↗ |
| Modality | Other / unclassified | “Ateronon, a nutritional supplement that contains lycopene from tomatoes” NCT00939237 ↗ |
| Route | Oral | “oral lycopene 15 or 30 mg per day for 12 weeks” NCT00154843 ↗ |
| Target | PCNA | “lycopene seems to be able to suppress significantly PCNA (Proliferating cell nuclear antigen, cofactor of DNA polymerase-β)” NCT03167268 ↗ |